	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	5,263	6,358	7,224	8,651	9,427	9,377	11,905	13,166	14,253	14,404	15,110	17,237	19,547	23,242	27,148
Cost of Operating Revenue	2,093	2,811	3,219	3,865	3,881	4,293	5,277	5,904	6,204	6,112	6,962	7,779	7,805	8,147	8,701
Gross Profit	3,170	3,547	4,005	4,786	5,546	5,083	6,628	7,262	8,049	8,291	8,148	9,458	11,742	15,095	18,448
Gross Margin	60.2	55.8	55.4	55.3	58.8	54.2	55.7	55.2	56.5	57.6	53.9	54.9	60.1	64.9	68.0
Total Operating Expenses	4,320	5,412	6,222	7,169	7,387	7,845	9,594	10,783	12,152	11,668	12,636	14,385	15,008	17,262	21,362
Operating Profit	943	945	1,002	1,483	2,039	1,532	2,311	2,382	2,102	2,736	2,474	2,853	4,539	5,979	5,787
Operating Margin	17.9	14.9	13.9	17.1	21.6	16.3	19.4	18.1	14.7	19.0	16.4	16.6	23.2	25.7	21.3
Financing Income/(Expense) - Net	-164	-141	-54	-41	10	13	-41	-140	-309	-123	98	231	128	184	842
Profit before Taxes	794	809	942	1,446	2,099	1,615	2,331	2,382	1,495	2,399	2,838	2,590	4,809	6,027	6,621
Income Taxes	113	119	106	259	177	129	564	530	320	194	512	588	978	1,412	1,595
Profit after Tax	653	654	804	1,151	1,934	1,488	1,776	1,849	1,177	2,134	4,487	1,960	3,860	4,526	5,040
PAT Margin	12.4	10.3	11.1	13.3	20.5	15.9	14.9	14.0	8.3	14.8	29.7	11.4	19.7	19.5	18.6
EPS - Basic - ex Extraordinary Items	6.37	6.38	7.85	11.22	3.78	14.56	17.53	18.06	11.49	21.51	21.90	19.35	37.91	44.97	50.09
EPS - Diluted - ex Extraordinary Items	6.37	6.38	7.85	11.22	3.78	14.56	17.53	18.06	11.49	21.51	21.90	19.35	37.91	44.97	50.09
EBIT	943	945	1,002	1,483	2,039	1,532	2,311	2,382	2,102	2,736	2,474	2,853	4,539	5,979	5,787
EBITDA	1,101	1,130	1,200	1,770	2,335	1,912	2,850	2,984	2,798	3,405	3,187	3,576	5,303	6,895	7,195
EBITDA Margin	20.9	17.8	16.6	20.5	24.8	20.4	23.9	22.7	19.6	23.6	21.1	20.7	27.1	29.7	26.5

Balance Sheet

Abridged

Understanding Balance Sheet

Zydus Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	2,813	3,192	3,438	4,089	4,280	6,022	8,230	8,498	8,715	8,716	12,261	10,016	11,501	17,046	19,906
Long-Term Investments	21	21	22	72	50	64	110	95	201	274	561	761	553	414	632
Property Plant & Equipment - Net	2,238	2,756	3,049	3,118	3,558	4,834	5,343	5,943	6,194	6,333	6,423	6,827	6,915	7,360	10,396
Total Non-Current Assets	2,586	4,183	4,549	5,046	6,270	9,198	9,836	14,985	14,971	15,169	15,534	15,740	17,779	20,156	32,501
Total Assets	6,423	7,374	7,987	9,134	10,551	15,221	18,065	23,483	23,687	23,885	27,795	25,756	29,281	37,202	52,407
Total Current Liabilities	2,192	2,670	2,814	2,992	3,461	5,306	6,083	7,343	8,269	7,861	7,839	5,531	5,342	9,042	15,712
Long Term Debt	1,322	1,426	1,362	1,150	896	2,468	2,555	3,950	3,229	625	378	20	25	32	3,856
Total Non-Current Liabilities	1,555	1,640	1,589	1,445	1,255	2,799	3,047	4,461	3,707	1,094	902	537	1,837	1,802	7,113
Total Liabilities	3,747	4,310	4,403	4,437	4,716	8,105	9,130	11,804	11,976	8,955	8,742	6,068	7,179	10,843	22,824
Total Shareholders' Equity	2,586	2,945	3,439	4,521	5,699	6,960	8,745	10,386	10,376	12,992	17,000	17,516	19,830	23,953	27,111
Minority Interest	90	119	144	177	136	156	191	1,293	1,335	1,937	2,054	2,173	2,272	2,405	2,471
Total Equity	2,676	3,064	3,583	4,698	5,835	7,116	8,936	11,679	11,710	14,930	19,054	19,688	22,102	26,358	29,582
Total Liabilities & Equity	6,423	7,374	7,987	9,134	10,551	15,221	18,065	23,483	23,687	23,885	27,795	25,756	29,281	37,202	52,407

Cash Flow

Abridged

Understanding Cash Flow Statement

Zydus Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	828	702	898	1,370	1,600	1,745	2,283	2,228	2,521	2,966	2,195	2,876	4,186	5,338	4,815
Working Capital - Increase/(Decrease)	-445	-231	-45	-402	313	-432	-1,419	-972	129	187	-352	-236	-903	1,532	-2,624
Net CF from Operating Activities	383	471	853	968	1,912	1,314	864	1,256	2,650	3,153	1,844	2,640	3,284	6,870	2,191
Capital Expenditures - Net	1,237	713	473	496	957	2,935	1,035	1,046	889	847	1,055	992	883	1,661	3,369
Net CF from Investing Activities	-1,234	-714	-474	-507	-927	-2,930	-1,024	-4,292	-1,045	-773	1,095	1,457	-1,604	-8,555	-8,725
Dividends Paid - Cash - Total	127	152	153	184	572	327	-	358	717	2	372	267	621	303	1,106
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	987	-	-863	-725	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	1,198	629	-223	-49	-202	2,765	157	2,396	-349	-3,211	-385	-3,144	-392	2,406	7,267
Net Cash Flow from Financing Activities	1,023	450	-442	-284	-891	2,371	156	1,964	-1,206	-2,358	-757	-4,274	-1,738	2,104	6,161
Free Cash Flow to Equity	344	387	156	424	754	1,144	-14	2,605	1,412	-905	404	-1,495	2,009	7,615	6,089
Free Operating CF net dividend	-997	-405	216	272	377	-1,953	-185	-160	1,029	2,297	269	1,342	1,756	4,855	-2,309
Free Operating CF	-871	-253	369	456	950	-1,626	-185	199	1,746	2,299	641	1,609	2,377	5,157	-1,203

Business Segment Analysis

FY End:

Mar 25

Zydus Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharmaceuticals (88.4%)₹ 20,543.90 CrConsumer products (11.6%)₹ 2,697.60 Cr

Assets

Pharmaceuticals (82.7%)₹ 30,762.80 CrConsumer products (17.3%)₹ 6,438.90 Cr

Regional Segment Analysis

FY End:

Mar 25

Zydus Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

US (47.9%)₹ 11,141.10 CrIndia (39.8%)₹ 9,253.00 CrOthers (12.3%)₹ 2,847.40 Cr

Historical Segment Analysis

Track how Zydus Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Assets

Business

Regional

Business

We don't have enough data to show the Capex for Zydus Lifesciences Ltd..

Frequently Asked Questions

What is the revenue of Zydus Lifesciences Ltd.?

The latest trailing twelve month revenue of Zydus Lifesciences Ltd. is ₹ 27,148.40 Cr, reflecting a 1-year growth of 16.81% and a 3-year CAGR of 16.35%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Zydus Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Zydus Lifesciences Ltd. is ₹ 5,040.00 Cr, with a 3-year earnings CAGR of 37.32%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Zydus Lifesciences Ltd.?

The trailing twelve month EBITDA of Zydus Lifesciences Ltd. is approximately ₹ 5,786.60 Cr (based on an operating margin of 21.31%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Zydus Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Zydus Lifesciences Ltd. is 50.09. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Zydus Lifesciences Ltd.?

The debt-to-equity ratio of Zydus Lifesciences Ltd. stands at 0.46. The interest coverage ratio is 13.18x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Zydus Lifesciences Ltd.?

The estimated book value per share of Zydus Lifesciences Ltd. is 274.63 (derived from a P/B ratio of 4.22 and market price of ₹ 1,160.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Zydus Lifesciences Ltd.?

The trailing twelve month operating cash flow of Zydus Lifesciences Ltd. is ₹ 2,191.40 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Zydus Lifesciences Ltd. report consolidated or standalone financials?

Zydus Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.